An Open-Label, Phase I Study on the Safety and Pharmacokinetics of Single and Multiple Oral Doses of AST1306 Tablets (AllitinibTosylate) in Chinese Cancer Patients.
Phase of Trial: Phase I
Latest Information Update: 21 May 2012
At a glance
- Drugs Allitinib (Primary)
- Indications Advanced breast cancer; Gastric cancer; Lung cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 21 May 2012 Planned End Date changed from 1 Mar 2011 to 30 Jun 2011 as reported by Chinese Clinical Trial Register.
- 11 Jun 2010 New trial record